IFIH1 and dermatomyositis: Therapeutic choices increasingly follow immune circuits rather than disease names: interferon-driven signatures respond to IFN blockade, anti-MDA5 dermatomyositis requires early combination therapy, anti-HMGCR myopathy relies on IVIG.